DDIT3 and diffuse large B-cell lymphoma: Thus, these findings suggest that antagomiRs for hsa-miR-146b and hsa-miR-222 can be used as adjuvant therapy to anthracycline-based chemotherapy (R-CHOP) in EBV+DLBCLe, which we confirmed has a poorer prognosis than DLBCL, NOS.